Calculus Capital Ltd. — 2025 Investments

1 investments dated 2025 · listed companies and verified rows first · show all

Trogenixtrogenixbio.com inOct 2025

Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.

BiotechDeep TechHealthtech

Co-investorsAIN Ventures IQ Capital 4BIO Capital LongeVC

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.